摘要
目的观察聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)在乳腺癌新辅助化疗后的应用效果。方法40例乳腺癌新辅助化疗患者,采用抛银币法分为对照组和实验组,每组20例。对照组在新辅助化疗48 h后接受重组人粒细胞集落刺激因子(rhG-CSF)治疗,实验组在新辅助化疗48 h后接受聚乙二醇化重组人粒细胞集落刺激因子治疗。比较两组治疗后粒细胞减少发生情况,粒细胞缺乏持续时间、发热持续时间,治疗后生活质量评分与白细胞计数(WBC)/中性粒细胞计数(ANC)情况,不良反应发生情况,骨髓抑制发生情况。结果治疗后,实验组的粒细胞减少发生率为10%(2/20),低于对照组的40%(8/20),差异有统计学意义(χ^(2)=4.800,P=0.028<0.05)。实验组的粒细胞缺乏持续时间、发热持续时间分别为(5.31±2.41)、(6.71±1.40)d,均短于对照组的(7.14±2.93)、(10.47±2.58)d,差异有统计学意义(P<0.05)。治疗后,实验组的生活质量评分(92.62±5.16)分显著高于对照组的(74.12±3.25)分,差异有统计学意义(P<0.05);实验组的WBC/ANC恢复正常时间(4.26±0.58)d短于对照组的(7.98±1.02)d,WBC/ANC维持正常时间(10.29±2.74)d长于对照组的(6.18±2.88)d,差异有统计学意义(P<0.05)。实验组的不良反应发生率20%低于对照组的60%,差异有统计学意义(P<0.05)。实验组的骨髓抑制发生率15%显著低于对照组的45%,差异有统计学意义(P<0.05)。结论聚乙二醇化重组人粒细胞集落刺激因子用于乳腺癌新辅助化疗后,可以有效改善患者的生活质量,促进预后,减少不良反应,具有广泛应用价值。
Objective To observe the application effect of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)after neoadjuvant chemotherapy for breast cancer.Methods A total of 40 patients with neoadjuvant chemotherapy for breast cancer were divided into a control group and an experimental group by silver coin tossing method,with 20 cases in each group.The control group received recombinant human granulocyte colony-stimulating factor(rhG-CSF)at 48 h after neoadjuvant chemotherapy,and the experimental group received pegylated recombinant human granulocyte colony-stimulating factor at 48 h after neoadjuvant chemotherapy.Both groups were compared in terms of occurrence of granulocytopenia,duration of agranulocytosis,duration of fever,quality of life score and white blood cell count(WBC)/absolute neutrophil count(ANC)after treatment,occurrence of adverse reactions and myelosuppression after treatment.Results After treatment,the incidence of granulocytopenia in the experimental group was 10%(2/20),which was lower than that 2 of 40%(8/20)in the control group,and the difference was statistically significant(χ^(2)=4.800,P=0.028<0.05).The duration of agranulocytosis and fever in the experimental group were(5.31±2.41)and(6.71±1.40)d,which were shorter than those of(7.14±2.93)and(10.47±2.58)d in the control group,and the differences were statistically significant(P<0.05).After treatment,the quality of life score of(92.62±5.16)points in the experimental group was significantly higher than that of(74.12±3.25)points in the control group,and the difference was statistically significant(P<0.05).WBC/ANC recovery time of(4.26±0.58)d in the experimental group was shorter than that of(7.98±1.02)d in the control group,and WBC/ANC maintenance time of(10.29±2.74)d was longer than that of(6.18±2.88)d in the control group.The differences were statistically significant(P<0.05).The incidence of adverse reactions of 20%in the experimental group was lower than that of 60%in the control group,and the difference was statistically significant(P<0.05).The incidence of myelosuppression of 15%in the experimental group was significantly lower than that of 45%in the control group,and the difference was statistically significant(P<0.05).Conclusion The use of pegylated recombinant human granulocyte colony-stimulating factor after neoadjuvant chemotherapy for breast cancer can effectively improve the quality of life of patients,promote the prognosis,and reduce adverse reactions,which has widespread application value.
作者
高富存
韩一浩
田娟
叶晖
李玉舟
张丽萍
赵淑婷
GAO Fu-cun;HAN Yi-hao;TIAN Juan(Linyi Central Hospital,Linyi 276400,China)
出处
《中国实用医药》
2023年第22期1-5,共5页
China Practical Medicine
基金
聚乙二醇化重组人粒细胞刺激因子在乳腺癌术后粒缺性发热发生中低风险化疗方案中的应用研究(项目编号:YXH2022ZX02166)。
关键词
聚乙二醇化重组人粒细胞集落刺激因子
乳腺癌
新辅助化疗
Pegylated recombinant human granulocyte colony-stimulating factor
Breast cancer
Neoadjuvant chemotherapy
